Full Press Release Details
Partners with Chang'an Pilot to Launch World-Class Joint Laboratory for Natural Ingredient Bio-manufacturing
China - Feb. 17, 2026 - Bon Natural Life Limited (Nasdaq: BON) ("BON"or the "Company"), a leading
bio-ingredient provider for the natural health and personal care industries, today announced the establishment of the BON & Pilot
Joint Laboratory for Natural Ingredients and Bio-Manufacturing (the "Joint Laboratory"). The Joint Laboratory was inaugurated
on December 18, 2025 through a collaboration between the Company's domestic operating subsidiary, Xi'an App-Chem Bio-Tech
Co., Ltd., and Shaanxi Chang'an Pilot Life Science Industry Innovation Center Co., Ltd. ("Chang'an Pilot").
Joint Laboratory will focus on the research and development of bio-manufactured natural active ingredients for use in functional foods
and personal care products. Through the integration of fermentation-based biosynthesis, natural compound isolation, and artificial intelligence-enabled
process optimization, the Joint Laboratory is intended to support the Company's efforts to improve production efficiency, supply
reliability, and environmental sustainability compared to traditional plant-based extraction methods.
in 2006, BON operates in the development, manufacturing, and commercialization of natural active ingredients for applications in health
and personal care products. The Company's product portfolio includes plant-derived extracts, functional food ingredients, and personal
care actives. BON serves customers in China, North America, the European Union, Japan, South Korea, and other international markets.
possesses technical capabilities in natural ingredient extraction, separation, and biosynthesis, supported by a proprietary artificial
intelligence-enabled bio-manufacturing research and development platform designed to integrate data analytics and process engineering
for scalable production.
Pilot, established in 2022, provides laboratory infrastructure and research services focused on life sciences and artificial intelligence-enabled
manufacturing technologies.
Hu, Chairman of BON, stated, "We believe the establishment of this Joint Laboratory will strengthen our research capabilities and
create meaningful collaboration between our respective teams. We expect this initiative will support our continued efforts to develop
scalable, high-quality natural ingredients and advance our long-term growth strategy."
Bon Natural Life Limited ("BON")
is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit
the Company's website at http://www.bnlus.com.
more information, please contact:
press release contains certain statements that may include "forward-looking statements." All statements other than statements
of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified
by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known
and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements
are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not
place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's
actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors,
including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available
on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly
qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to
update these forward-looking statements.